Release and elimination of 14C-fluphenazine enanthate and decanoate esters administered in sesame oil to dogs
- PMID: 1271246
- DOI: 10.1002/jps.2600650407
Release and elimination of 14C-fluphenazine enanthate and decanoate esters administered in sesame oil to dogs
Abstract
The rates of release of 14C-fluphenazine enanthate and 14C-fluphenazine decanoate were compared in two groups of five male dogs. Each dog was given a single dose (2 mg/kg im) of either the enanthate or decanoate ester in sesame oil. The times required to attain maximum concentrations of radioactivity in plasma were 3.8 +/- 0.5 days (+/-SE) for the enanthate ester and 10.6 +/- 1.1 days for the decanoate ester (p less than 0.001); maximum concentrations of radioactivity in the plasma at these times were 16.7 +/- 1.1 and 11.1 +/- 1.2 ng/ml, respectively (p less than 0.01). However, 35 days after dosing, the concentrations of radioactivity in plasma were greater for the decanoate ester than for the enanthate ester. The times required for 50% of the dose to be excreted in the urine and feces were 7.8 +/- 0.5 days for the enanthate ester and 22.6 +/- 4.4 days for the decanoate ester (p less than 0.05). The total amounts excreted in 35 days were 85.4 +/- 1.8 and 68.8 +/- 6.6% of the dose for the enanthate and decanoate esters, respectively; the average half-times for the rates of release of radioactivity from depot and body, as calculated from the data for total excretion, were 5.55 days for the enanthate ester and 15.4 days for the decanoate ester. Thirty-five days after dosing, the amount of the dose present in the injection site was 4.6 +/- 1.6% for the enanthate ester and 18.6 +/- 5.7% for the decanoate ester. Two groups of six dogs each were protected against the emetic effects of apomorphine more than twice as long by the decanoate ester than by the enanthate ester after the subcutaneous administration of single 8-mg/kg doses of either drug in sesame oil (p less than 0.05). Based on measurements of total radioactivity, it was concluded that the decanoate ester was released from the depot at less than one-half the rate of the enanthate ester.
Similar articles
-
Clinical pharmacokinetics of the depot antipsychotics.Clin Pharmacokinet. 1985 Jul-Aug;10(4):315-33. doi: 10.2165/00003088-198510040-00003. Clin Pharmacokinet. 1985. PMID: 2864156 Review.
-
Fluphenazine enanthate and fluphenazine decanoate: intramuscular injection and esterification as requirements for slow - release characteristics in dogs.J Pharm Sci. 1976 Sep;65(9):1310-5. doi: 10.1002/jps.2600650912. J Pharm Sci. 1976. PMID: 966144
-
Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man.Br J Clin Pharmacol. 1979 Apr;7(4):325-31. doi: 10.1111/j.1365-2125.1979.tb00941.x. Br J Clin Pharmacol. 1979. PMID: 444352 Free PMC article.
-
Depot fluphenazine enanthate and decanoate: comparative rates of release in dogs.J Pharm Pharmacol. 1975 Oct;27(10):791-2. doi: 10.1111/j.2042-7158.1975.tb09407.x. J Pharm Pharmacol. 1975. PMID: 241800 No abstract available.
-
Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review.Arzneimittelforschung. 2001 Sep;51(9):699-725. doi: 10.1055/s-0031-1300105. Arzneimittelforschung. 2001. PMID: 11642003 Review.
Cited by
-
Critical factors influencing the in vivo performance of long-acting lipophilic solutions--impact on in vitro release method design.AAPS J. 2009 Dec;11(4):762-70. doi: 10.1208/s12248-009-9153-9. Epub 2009 Nov 6. AAPS J. 2009. PMID: 19894123 Free PMC article. Review.
-
Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.Br J Clin Pharmacol. 1979 Dec;8(6):565-70. doi: 10.1111/j.1365-2125.1979.tb01045.x. Br J Clin Pharmacol. 1979. PMID: 533577 Free PMC article.
-
Clinical pharmacokinetics of the depot antipsychotics.Clin Pharmacokinet. 1985 Jul-Aug;10(4):315-33. doi: 10.2165/00003088-198510040-00003. Clin Pharmacokinet. 1985. PMID: 2864156 Review.
-
Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies.Drug Deliv Transl Res. 2025 Apr;15(4):1156-1180. doi: 10.1007/s13346-024-01747-y. Epub 2024 Dec 11. Drug Deliv Transl Res. 2025. PMID: 39661312 Free PMC article. Review.
-
Polymer Delivery Systems for Long-Acting Antiretroviral Drugs.Pharmaceutics. 2024 Jan 28;16(2):183. doi: 10.3390/pharmaceutics16020183. Pharmaceutics. 2024. PMID: 38399244 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources